Standard
Response to pegylated interferon in a COVID-19–positive elderly woman with primary myelofibrosis treated with ruxolitinib. / Frankel, Arthur E.; Reddy, Renuka; DeSuza, Kayla R.; Deeb, Khaled; Carlin, Aaron F.; Smith, Davey; Xie, Yushuang; Naik, Eknath; Silver, Richard T.; Hasselbalch, Hans C.
I:
Clinical Case Reports, Bind 9, Nr. 4, 2021, s. 2228-2235.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Frankel, AE, Reddy, R, DeSuza, KR, Deeb, K, Carlin, AF, Smith, D, Xie, Y, Naik, E, Silver, RT
& Hasselbalch, HC 2021, '
Response to pegylated interferon in a COVID-19–positive elderly woman with primary myelofibrosis treated with ruxolitinib',
Clinical Case Reports, bind 9, nr. 4, s. 2228-2235.
https://doi.org/10.1002/ccr3.3997APA
Frankel, A. E., Reddy, R., DeSuza, K. R., Deeb, K., Carlin, A. F., Smith, D., Xie, Y., Naik, E., Silver, R. T.
, & Hasselbalch, H. C. (2021).
Response to pegylated interferon in a COVID-19–positive elderly woman with primary myelofibrosis treated with ruxolitinib.
Clinical Case Reports,
9(4), 2228-2235.
https://doi.org/10.1002/ccr3.3997Vancouver
Frankel AE, Reddy R, DeSuza KR, Deeb K, Carlin AF, Smith D o.a.
Response to pegylated interferon in a COVID-19–positive elderly woman with primary myelofibrosis treated with ruxolitinib.
Clinical Case Reports. 2021;9(4):2228-2235.
https://doi.org/10.1002/ccr3.3997Author
Frankel, Arthur E. ; Reddy, Renuka ; DeSuza, Kayla R. ; Deeb, Khaled ; Carlin, Aaron F. ; Smith, Davey ; Xie, Yushuang ; Naik, Eknath ; Silver, Richard T. ; Hasselbalch, Hans C. / Response to pegylated interferon in a COVID-19–positive elderly woman with primary myelofibrosis treated with ruxolitinib. I: Clinical Case Reports. 2021 ; Bind 9, Nr. 4. s. 2228-2235.
Bibtex
@article{5489297ccca04e1486b2343692bd52cb,
title = "Response to pegylated interferon in a COVID-19–positive elderly woman with primary myelofibrosis treated with ruxolitinib",
abstract = "An 83-year-old female had asymptomatic SARS-CoV-2 infection while taking ruxolitinib. She remained RT-PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID-19.",
keywords = "COVID-19, interferon, ruxolitinib",
author = "Frankel, {Arthur E.} and Renuka Reddy and DeSuza, {Kayla R.} and Khaled Deeb and Carlin, {Aaron F.} and Davey Smith and Yushuang Xie and Eknath Naik and Silver, {Richard T.} and Hasselbalch, {Hans C.}",
note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.",
year = "2021",
doi = "10.1002/ccr3.3997",
language = "English",
volume = "9",
pages = "2228--2235",
journal = "Clinical Case Reports",
issn = "2050-0904",
publisher = "JohnWiley & Sons Ltd",
number = "4",
}
RIS
TY - JOUR
T1 - Response to pegylated interferon in a COVID-19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
AU - Frankel, Arthur E.
AU - Reddy, Renuka
AU - DeSuza, Kayla R.
AU - Deeb, Khaled
AU - Carlin, Aaron F.
AU - Smith, Davey
AU - Xie, Yushuang
AU - Naik, Eknath
AU - Silver, Richard T.
AU - Hasselbalch, Hans C.
N1 - Publisher Copyright:
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
PY - 2021
Y1 - 2021
N2 - An 83-year-old female had asymptomatic SARS-CoV-2 infection while taking ruxolitinib. She remained RT-PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID-19.
AB - An 83-year-old female had asymptomatic SARS-CoV-2 infection while taking ruxolitinib. She remained RT-PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID-19.
KW - COVID-19
KW - interferon
KW - ruxolitinib
U2 - 10.1002/ccr3.3997
DO - 10.1002/ccr3.3997
M3 - Journal article
C2 - 33936671
AN - SCOPUS:85102203722
VL - 9
SP - 2228
EP - 2235
JO - Clinical Case Reports
JF - Clinical Case Reports
SN - 2050-0904
IS - 4
ER -
